{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:56:52Z","timestamp":1784339812382,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T00:00:00Z","timestamp":1422489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10067-015-2883-4","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T06:29:59Z","timestamp":1422426599000},"page":"1341-1345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of osteoporosis in renal insufficiency"],"prefix":"10.1007","volume":"34","author":[{"given":"Lydia G.","family":"Schipper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W. H. A.","family":"Fleuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop P. W.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan R.","family":"Meinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A. J.","family":"Veldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Kramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,29]]},"reference":[{"key":"2883_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","volume":"74","author":"TL Nickolas","year":"2008","unstructured":"Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721\u2013731","journal-title":"Kidney Int"},{"key":"2883_CR2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00198-011-1775-y","volume":"23","author":"S Silverman","year":"2012","unstructured":"Silverman S, Christiansen C (2012) Individualizing osteoporosis therapy. Osteoporos Int 23:797\u2013809","journal-title":"Osteoporos Int"},{"key":"2883_CR3","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1297-319X(12)70017-9","volume":"79","author":"J Cesini","year":"2012","unstructured":"Cesini J, Cheriet S, Breuil V, Lafage-Proust MH (2012) Osteoporosis: chronic kidney disease in rheumatology practice. Joint Bone Spine 79:S104\u2013S109","journal-title":"Joint Bone Spine"},{"key":"2883_CR4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/BOR.0000000000000074","volume":"26","author":"S Bours","year":"2014","unstructured":"Bours S, van den Bergh J, van Geel T, Geusens P (2014) Secondary osteoporosis and metabolic bone disease in patients 50\u00a0years and older with osteoporosis or with a recent clinical fracture: a clinical perspective. Curr Opin Rheumatol 26:430\u2013439","journal-title":"Curr Opin Rheumatol"},{"key":"2883_CR5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1797.2009.01159.x","volume":"14","author":"SM Ott","year":"2009","unstructured":"Ott SM (2009) Review article: bone density in patients with chronic kidney disease stages 4\u20135. Nephrol (Carlton) 14:395\u2013403","journal-title":"Nephrol (Carlton)"},{"key":"2883_CR6","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"PD Miller","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28:2049\u20132059","journal-title":"J Bone Miner Res"},{"key":"2883_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11926-012-0243-9","volume":"14","author":"SA Jamal","year":"2012","unstructured":"Jamal SA, West SL, Miller PD (2012) Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep 14:217\u2013223","journal-title":"Curr Rheumatol Rep"},{"key":"2883_CR8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11914-005-0021-y","volume":"3","author":"PD Miller","year":"2005","unstructured":"Miller PD (2005) Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 3:5\u201312","journal-title":"Curr Osteoporos Rep"},{"key":"2883_CR9","first-page":"1","volume":"8","author":"SM Ott","year":"2013","unstructured":"Ott SM (2013) Therapy for patients with CKD and low bone mineral density. Nat Rev Nephrol 8:1\u201312","journal-title":"Nat Rev Nephrol"},{"key":"2883_CR10","unstructured":"Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Osteoporose en fractuurpreventie, derde herziening. Alphen aan den Rijn: Van Zuiden Communications; 2011. www.diliguide.nl"},{"key":"2883_CR11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","volume":"64","author":"PD Miller","year":"2014","unstructured":"Miller PD (2014) Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64:290\u2013304","journal-title":"Am J Kidney Dis"},{"key":"2883_CR12","first-page":"140","volume":"113","author":"BL Kasiske","year":"2009","unstructured":"Kasiske BL, Zeier MG, Chapman JR et al (2009) KDIGO: clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney Int Suppl 113:140","journal-title":"Kidney Int Suppl"},{"key":"2883_CR13","unstructured":"Commissie Farmaceutische Hulp. Osteoporose. In: Farmacotherapeutisch kompas. Amstelveen: College voor zorgverzekeringen, 2014. http:\/\/www.farmacotherapeutischkompas.nl\/inleidendeteksten\/osteoporose"},{"key":"2883_CR14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281\u2013289","journal-title":"Kidney Int"},{"key":"2883_CR15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00198-011-1836-2","volume":"23","author":"M Yilmaz","year":"2012","unstructured":"Yilmaz M, Taninmis H, Kara E, Ozagari A, Unsal A (2012) Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. Case report. Osteoporos Int 23:2059\u20132062","journal-title":"Osteoporos Int"},{"key":"2883_CR16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385\u20131393","journal-title":"Kidney Int"},{"key":"2883_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10157-008-0078-x","volume":"13","author":"N Miura","year":"2009","unstructured":"Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H (2009) Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol 13:85\u201388","journal-title":"Clin Exp Nephrol"},{"key":"2883_CR18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE (2008) The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19:1430\u20131438","journal-title":"J Am Soc Nephrol"},{"key":"2883_CR19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A et al (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503\u2013508","journal-title":"J Bone Miner Res"},{"key":"2883_CR20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/ki.2012.227","volume":"82","author":"AW Shih","year":"2012","unstructured":"Shih AW, Weir MA, Clemens KK, Yao Z, Gomes T, Mamdani MM et al (2012) Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int 82:903\u2013908","journal-title":"Kidney Int"},{"key":"2883_CR21","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one\u2010year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"2883_CR22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2011.09.035","volume":"49","author":"PD Miller","year":"2011","unstructured":"Miller PD, Ragi\u2010Eis S, Mautalan C, Ramirez F, Jonkanski I (2011) Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease\u2014the DIVINE study. Bone 49:1317\u20131322","journal-title":"Bone"},{"key":"2883_CR23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P et al (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74:641\u2013648","journal-title":"Kidney Int"},{"key":"2883_CR24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"2883_CR25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835","journal-title":"J Bone Miner Res"},{"key":"2883_CR26","first-page":"542","volume":"34","author":"AE Sirvent","year":"2014","unstructured":"Sirvent AE, Enr\u00edquez R, S\u00e1nchez M, Gonz\u00e1lez C, Mill\u00e1n I, Amor\u00f3s F (2014) Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease? Nefrologia 34:542\u2013544","journal-title":"Nefrologia"},{"key":"2883_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ki.2010.378","volume":"79","author":"ML Melamed","year":"2011","unstructured":"Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, Ishani A et al (2011) Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int 79:241\u2013249","journal-title":"Kidney Int"},{"key":"2883_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","volume":"68","author":"M Cozzolino","year":"2005","unstructured":"Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68:429\u2013436","journal-title":"Kidney Int"},{"key":"2883_CR29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmj.328.7435.335","volume":"328","author":"R Peter","year":"2004","unstructured":"Peter R, Mishra V, Fraser WD (2004) Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 328:335\u2013336","journal-title":"BMJ"},{"key":"2883_CR30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"2883_CR31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD et al (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291\u2013297","journal-title":"Osteoporos Int"},{"key":"2883_CR32","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/imj.12283","volume":"43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 43:1243\u20131246","journal-title":"Intern Med J"},{"key":"2883_CR33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00198-010-1177-6","volume":"22","author":"A Kyrgidis","year":"2011","unstructured":"Kyrgidis A, Toulis KA (2011) Denosumab-related osteonecrosis of the jaws. Osteoporos Int 22:369\u2013370","journal-title":"Osteoporos Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2883-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-2883-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2883-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:39Z","timestamp":1559120259000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-2883-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,29]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-2883-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,29]]}}}